Publication of Circular

Verici Dx PLC

26 January 2024

 

26 January 2024

Verici Dx plc

("Verici" or the "Company")

Publication of Circular

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that, further to the announcement made at 7.00 a.m. on 24 January 2024 (RNS Number 6987A), the Circular has been published today. The Circular will be posted to Shareholders that have elected to receive hard copies of Shareholder documentation today and will also be available later today on the Company's website at https://vericidx.com/investors/documents/.

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via IR-Connect
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher / Jalini Kalaravy
IR-Connect	www.ir-connect.co.uk
Lorraine Rees	[e-mail]

About Verici Dx plc www.vericidx.com

Verici is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END